DMK Pharmaceuticals Gross Profit

The latest gross profit for DMK is $-1.4M as of December 2022. That compares with $-4.7M in the prior-year period — up 69.3% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside DMK Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, DMK's gross profit moved from $-4.7M to $-1.4M — a 69.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in DMK Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, DMK currently prints $-1.4M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at DMK Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $-1.4M for DMK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting DMK's gross profit ($-1.4M), review year-over-year change from $-4.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.